Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
University of Michigan Rogel Cancer Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06616155CT.gov Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT07620574CT.gov Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | — | Not Yet Recruiting | — | — | — |
NCT07512076CT.gov A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer | — | Not Yet Recruiting | — | — | — |
NCT07230106CT.gov A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer | — | Recruiting | — | — | — |
NCT07198633CT.gov A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT07028853CT.gov This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | — | Recruiting | — | — | — |
NCT07104643CT.gov Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） | — | Not Yet Recruiting | — | — | — |
NCT07406282CT.gov A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics | — | Recruiting | — | — | — |
NCT07086651CT.gov A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC) | — | Completed | — | — | — |
NCT06991556CT.gov An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | — | Recruiting | — | — | — |
Show 134 more trialsShow fewer
NCT06855277CT.gov Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | — | Recruiting | — | — | — |
NCT05873192CT.gov Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | — | Recruiting | — | — | — |
NCT06632977CT.gov Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | — | Recruiting | — | — | — |
NCT05726292CT.gov A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | — | Recruiting | — | — | — |
NCT06130995CT.gov Relugolix + Enzalutamide Study in High-Risk Prostate Cancer | — | Recruiting | — | — | — |
NCT06652607CT.gov PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT06236139CT.gov Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06505278CT.gov The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy | — | Not Yet Recruiting | — | — | — |
NCT06457919CT.gov A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | — | Recruiting | — | — | — |
NCT06378866CT.gov Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial | — | Recruiting | — | — | — |
NCT05627752CT.gov Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage | — | Unknown | — | — | — |
NCT06430411CT.gov Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | — | Not Yet Recruiting | — | — | — |
NCT06312670CT.gov Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT06096870CT.gov Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy | — | Recruiting | — | — | — |
NCT05730712CT.gov Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT06204302CT.gov An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States | — | Completed | — | — | — |
NCT06059118CT.gov Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT05733351CT.gov Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | — | Terminated | — | — | — |
NCT05901649CT.gov A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide | — | Active Not Recruiting | — | — | — |
NCT05818683CT.gov A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05751941CT.gov Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05683964CT.gov Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | — | Active Not Recruiting | — | — | — |
NCT05526248CT.gov A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide | — | Completed | — | — | — |
NCT05191017CT.gov Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | — | Withdrawn | — | — | — |
NCT05422911CT.gov Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. | — | Recruiting | — | — | — |
NCT05212857CT.gov Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer | — | Unknown | — | — | — |
NCT05252390CT.gov NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04655365CT.gov Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. | — | Active Not Recruiting | — | — | — |
NCT05081193CT.gov Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT05037500CT.gov Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT05011188CT.gov FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT05202301CT.gov A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely | — | Completed | — | — | — |
NCT05075577CT.gov EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC | — | Terminated | — | — | — |
NCT04455750CT.gov A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy | — | Active Not Recruiting | — | — | — |
NCT04335682CT.gov Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide | — | Completed | — | — | — |
NCT04729114CT.gov A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT04934722CT.gov Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension | — | Completed | — | — | — |
NCT04821622CT.gov Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | — | Active Not Recruiting | — | — | — |
NCT03709550CT.gov Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | — | Withdrawn | — | — | — |
NCT04471974CT.gov ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04557449CT.gov Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT07428642CT.gov PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC. | — | Completed | — | — | — |
NCT04409288CT.gov Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer | — | Terminated | — | — | — |
NCT03999515CT.gov Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | — | Terminated | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04207255CT.gov Addition of Opaganib to Androgen Antagonists in Patients With mCRPC | — | Completed | — | — | — |
NCT03478904CT.gov Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer | — | Terminated | — | — | — |
NCT04221542CT.gov Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04191096CT.gov Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) | — | Completed | — | — | — |
NCT05406999CT.gov Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT04094519CT.gov A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer | — | Completed | — | — | — |
NCT04145375CT.gov Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol | — | Enrolling By Invitation | — | — | — |
NCT04116775CT.gov Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. | — | Unknown | — | — | — |
NCT03700099CT.gov Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide | — | Unknown | — | — | — |
NCT04087174CT.gov A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT03751436CT.gov Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03300505CT.gov ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03860987CT.gov Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer | — | Completed | — | — | — |
NCT03809000CT.gov A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery | — | Active Not Recruiting | — | — | — |
NCT03734653CT.gov Testosterone Therapy in Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT04290611CT.gov a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY | — | Completed | — | — | — |
NCT03753243CT.gov Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer | — | Recruiting | — | — | — |
NCT03344211CT.gov Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03674814CT.gov Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer | — | Completed | — | — | — |
NCT03418324CT.gov Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy | — | Completed | — | — | — |
NCT03338790CT.gov An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer | — | Completed | — | — | — |
NCT03395197CT.gov Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC | — | Active Not Recruiting | — | — | — |
NCT03336983CT.gov Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients | — | Completed | — | — | — |
NCT03310541CT.gov AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | — | Completed | — | — | — |
NCT03246347CT.gov A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03124615CT.gov Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer | — | Unknown | — | — | — |
NCT03016741CT.gov Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02935205CT.gov Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | — | Unknown | — | — | — |
NCT02903160CT.gov Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | — | Completed | — | — | — |
NCT03123978CT.gov Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02960022CT.gov A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | — | Recruiting | — | — | — |
NCT06473259CT.gov Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients | — | Recruiting | — | — | — |
NCT02918968CT.gov Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02833883CT.gov Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02339168CT.gov Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02640534CT.gov Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone | — | Terminated | — | — | — |
NCT02799745CT.gov A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance | — | Completed | — | — | — |
NCT02452008CT.gov Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02601014CT.gov Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | — | Completed | — | — | — |
NCT02758132CT.gov Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases | — | Terminated | — | — | — |
NCT02685267CT.gov Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT02555189CT.gov Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | — | Terminated | — | — | — |
NCT02278185CT.gov Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT02194842CT.gov Phase III Radium 223 mCRPC-PEACE III | — | Active Not Recruiting | — | — | — |
NCT02588001CT.gov Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide | — | Completed | — | — | — |
NCT02491411CT.gov Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel | — | Terminated | — | — | — |
NCT02522715CT.gov Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02353715CT.gov Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing | — | Completed | — | — | — |
NCT02430480CT.gov Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer | — | Completed | — | — | — |
NCT02225704CT.gov Radium-223 in Combination With Enzalutamide | — | Completed | — | — | — |
NCT02438007CT.gov A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC | — | Terminated | — | — | — |
NCT02256111CT.gov EXTEND Exercise Trial | — | Completed | — | — | — |
NCT02366494CT.gov Micro RNAs to Predict Response to Androgen Deprivation Therapy | — | Completed | — | — | — |
NCT02319837CT.gov Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | — | Active Not Recruiting | — | — | — |
NCT02268175CT.gov Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | — | Completed | — | — | — |
NCT02125084CT.gov Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01990196CT.gov Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02124668CT.gov A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | — | Completed | — | — | — |
NCT02159690CT.gov A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | — | Withdrawn | — | — | — |
NCT02213107CT.gov Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. | — | Completed | — | — | — |
NCT03297385CT.gov Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation | — | Completed | — | — | — |
NCT02090114CT.gov RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) | — | Completed | — | — | — |
NCT02199197CT.gov Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer | — | Completed | — | — | — |
NCT02058706CT.gov LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT02064582CT.gov Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer | — | Completed | — | — | — |
NCT02294461CT.gov An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants | — | Completed | — | — | — |
NCT02023463CT.gov Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02057939CT.gov Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) | — | Completed | — | — | — |
NCT02028988CT.gov Enzalutamide + External Beam Rt For Prostate | — | Completed | — | — | — |
NCT01949337CT.gov Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | — | Unknown | — | — | — |
NCT02012296CT.gov Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02003924CT.gov Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01946165CT.gov Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide | — | Completed | — | — | — |
NCT01995513CT.gov Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients | — | Completed | — | — | — |
NCT02225093CT.gov A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer | — | Completed | — | — | — |
NCT01885949CT.gov Tivozanib + Enzalutamide in Adv Prostate Cancer | — | Terminated | — | — | — |
NCT01867333CT.gov Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer | — | Completed | — | — | — |
NCT01875250CT.gov Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT02228265CT.gov Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | — | Completed | — | — | — |
NCT01902251CT.gov Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients | — | Completed | — | — | — |
NCT01664923CT.gov Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer | — | Completed | — | — | — |
NCT01547299CT.gov Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer | — | Completed | — | — | — |
NCT01565928CT.gov Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer | — | Completed | — | — | — |
NCT01911728CT.gov Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates | — | Completed | — | — | — |
NCT01302041CT.gov A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy | — | Completed | — | — | — |
NCT01284920CT.gov A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | — | Completed | — | — | — |
NCT01212991CT.gov A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00510718CT.gov A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer | — | Completed | — | — | — |
NCT00268476CT.gov Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Enzalutamide (this asset) | University of Michigan Rogel Cancer Center | Approved | BB · 69 |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BBB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BBB |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BB |
| Goserelin | Bayer | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Flutamide | VA Office of Research and Development | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Enzalutamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P4 | BBB · 73 |
| Prostate Carcinoma | — | P4 | BB · 69 |
| Metastatic Prostate Carcinoma | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Enzalutamide in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/enzalutamide-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →